PURPOSE: Cytogenetics is an important prognostic parameter in multiple myeloma (MM). Patients presenting with either t(4;14) or del(17p) are known to have a short event-free survival (EFS) and overall survival (OS). Some preliminary data suggest that bortezomib is able to overcome these prognostic parameters. PATIENTS AND METHODS: A series of 507 patients with newly diagnosed MM who received four cycles of bortezomib-dexamethasone induction therapy before high-dose melphalan were analyzed for both t(4;14) and del(17p). RESULTS: We found that both t(4;14) and del(17p) remain prognostic parameters, even in the context of bortezomib treatment. However, it is important to note that bortezomib significantly improves the prognosis (in terms of both EFS and OS) of patients with t(4;14), compared with patients treated with vincristine, doxorubicin, and dexamethasone induction therapy. In contrast, no improvement was observed for del(17p) patients. CONCLUSION: Short-term bortezomib induction improves outcome of patients with t(4;14) but not the outcome of patients with del(17p). However, both abnormalities remain prognostic factors predicting both EFS and OS despite bortezomib induction.
PURPOSE: Cytogenetics is an important prognostic parameter in multiple myeloma (MM). Patients presenting with either t(4;14) or del(17p) are known to have a short event-free survival (EFS) and overall survival (OS). Some preliminary data suggest that bortezomib is able to overcome these prognostic parameters. PATIENTS AND METHODS: A series of 507 patients with newly diagnosed MM who received four cycles of bortezomib-dexamethasone induction therapy before high-dose melphalan were analyzed for both t(4;14) and del(17p). RESULTS: We found that both t(4;14) and del(17p) remain prognostic parameters, even in the context of bortezomib treatment. However, it is important to note that bortezomib significantly improves the prognosis (in terms of both EFS and OS) of patients with t(4;14), compared with patients treated with vincristine, doxorubicin, and dexamethasone induction therapy. In contrast, no improvement was observed for del(17p) patients. CONCLUSION: Short-term bortezomib induction improves outcome of patients with t(4;14) but not the outcome of patients with del(17p). However, both abnormalities remain prognostic factors predicting both EFS and OS despite bortezomib induction.
Authors: Hervé Avet-Loiseau; Rafael Fonseca; David Siegel; Meletios A Dimopoulos; Ivan Špička; Tamás Masszi; Roman Hájek; Laura Rosiñol; Vesselina Goranova-Marinova; Georgi Mihaylov; Vladimír Maisnar; Maria-Victoria Mateos; Michael Wang; Ruben Niesvizky; Albert Oriol; Andrzej Jakubowiak; Jiri Minarik; Antonio Palumbo; William Bensinger; Vishal Kukreti; Dina Ben-Yehuda; A Keith Stewart; Mihaela Obreja; Philippe Moreau Journal: Blood Date: 2016-07-20 Impact factor: 22.113
Authors: Sarah K Johnson; Christoph J Heuck; Anthony P Albino; Pingping Qu; Qing Zhang; Bart Barlogie; John D Shaughnessy Journal: Int J Hematol Date: 2011-10-15 Impact factor: 2.490
Authors: A K Nooka; J L Kaufman; S Muppidi; A Langston; L T Heffner; C Gleason; D Casbourne; D Saxe; L H Boise; S Lonial Journal: Leukemia Date: 2013-11-13 Impact factor: 11.528
Authors: Fabian Bock; Gary Lu; Samer A Srour; Sameh Gaballa; Heather Y Lin; Veerabhadran Baladandayuthapani; Medhavi Honhar; Maximilian Stich; Nina Das Shah; Qaiser Bashir; Krina Patel; Uday Popat; Chitra Hosing; Martin Korbling; Ruby Delgado; Gabriela Rondon; Jatin J Shah; Sheeba K Thomas; Elisabet E Manasanch; Berend Isermann; Robert Z Orlowski; Richard E Champlin; Muzaffar H Qazilbash Journal: Biol Blood Marrow Transplant Date: 2016-09-13 Impact factor: 5.742
Authors: H Avet-Loiseau; B G M Durie; M Cavo; M Attal; N Gutierrez; J Haessler; H Goldschmidt; R Hajek; J H Lee; O Sezer; B Barlogie; J Crowley; R Fonseca; N Testoni; F Ross; S V Rajkumar; P Sonneveld; J Lahuerta; P Moreau; G Morgan Journal: Leukemia Date: 2012-10-03 Impact factor: 11.528